Kyverna Therapeutics (KYTX) Current Assets (2023 - 2026)

Kyverna Therapeutics' Current Assets history runs 4 years deep, the most recent figure standing at $241.7 million for Q1 2026.

• Quarterly Current Assets fell 2.39% year-over-year to $241.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $241.7 million (down 2.39% YoY) and the FY2025 annual result came in at $283.0 million, down 2.63% from the prior year.
• Current Assets was $241.7 million for Q1 2026 at Kyverna Therapeutics, down from $283.0 million in the prior quarter.
• Across five years, Current Assets topped out at $375.5 million in Q1 2024 and bottomed at $60.7 million in Q4 2023.
• A 4-year average of $256.3 million and a median of $265.3 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets jumped 379.03% — and 2025, when it slumped 46.24%.
• Kyverna Therapeutics' Current Assets stood at $60.7 million in 2023, then jumped by 379.03% to $290.6 million in 2024, then fell by 2.63% to $283.0 million in 2025, then declined by 14.57% to $241.7 million in 2026.
• Business Quant data shows KYTX's Current Assets at $241.7 million in Q1 2026, $283.0 million in Q4 2025, and $174.9 million in Q3 2025.